For example, patients with GNAO1 and GNAI1 mutations are treated with anti-seizure medications to manage epilepsy and movement disorders (Muir et al, 2021; Sáez González et al, 2023), and dystonia is treated pharmacologically in GNAL patients (Salamon et al, 2023). This evidence concerns the gene GNAO1 and movement disorder.